Arca
Skip to content
Tools
Tools

TTR: Transthyretin

Thyroid hormone-binding protein.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on TTR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Tafamidis
  • Acoramidis

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        TafamidisApprovedPfizerSmall moleculeStabiliserTransthyretin stabiliser13
        AcoramidisApprovedBridgeBio PharmaSmall moleculeStabiliserTransthyretin stabiliser11

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 13 in all, from ClinicalTrials.gov.
        Study of Acoramidis in Patients With Transthyretin Amyloid CardiomyopathyAcoramidis—RecruitingBayerAug 27, 2026
        Liver and Coagulation Disorders in Cardiac Transthyretin AmyloidosisAcoramidis, Tafamidis—RecruitingUniversity of MessinaAug 14, 2026
        Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisAcoramidisPhase 4RecruitingEidos Therapeutics, a BridgeBio companyJul 10, 2026
        A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyTafamidis—Active, not recruitingPfizerMar 27, 2026
        Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac BiomarkersAcoramidisPhase 4RecruitingAlexion Pharmaceuticals, Inc.Dec 29, 2025
        A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisAcoramidis, TafamidisPhase 4RecruitingBayerDec 22, 2025
        A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world SettingAcoramidis—RecruitingBayerNov 19, 2025
        Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker StudyAcoramidis, Tafamidis—RecruitingUniversity of Texas Southwestern Medical CenterSep 29, 2025
        To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)AcoramidisPhase 3Not yet recruitingEidos Therapeutics, a BridgeBio companyAug 11, 2025
        To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid PolyneuropathyTafamidisPhase 4RecruitingQilu Pharmaceutical Co., Ltd.Apr 23, 2025
        NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on TafamidisTafamidis—RecruitingPaolo MilaniFeb 9, 2024
        Edge-to-edge Mitral Valve Repair in ATTR-CMTafamidisNot applicableRecruitingMedical University of ViennaOct 10, 2023
        Quantitative-imaging in Cardiac Transthyretin AmyloidosisTafamidis—RecruitingUniversity of EdinburghMar 20, 2023

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Amyloidosis, hereditary systemic 1
        0.85
        Hereditary ATTR amyloidosis
        0.81
        Carpal tunnel syndrome 1
        0.72
        Hereditary amyloidosis
        0.69
        AL amyloidosis
        0.65
        Cardiac amyloidosis
        0.57
        Abnormality of the cardiovascular system
        0.57
        ATTRV122I amyloidosis
        0.50

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3194, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P02766, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.